SOURCE: Paragon Financial Limited

Paragon Financial Limited

September 15, 2011 08:16 ET

Embryonic Stems Cell Researchers Free From Controversy for at Least One More Year

The Paragon Report Provides Equity Research on Advanced Cell Technology and Geron Corporation

NEW YORK, NY--(Marketwire - Sep 15, 2011) - The Paragon Report examines investing opportunities in the Biotechnology Industry and provides equity research on Advanced Cell Technology, Inc. (OTCBB: ACTC) and Geron Corporation (NASDAQ: GERN). Access to the full company reports can be found at:

While scientists from across the globe firmly believe that stem cells are the future of medicine, and a highly lucrative sector, stem cell stocks continue to be some of the most volatile as investors worry that potential budget cuts could slash funding for the controversial research.

North American embryonic stem cell researchers have at least one more year to bask in the tolerant Obama Administration. Since the president's inauguration, the Obama administration has argued it can fund research on stem cells derived from embryonic stem cell lines that were created with private money. Earlier this year a federal appeals court said the federal government can continue to fund research involving human embryonic stem cells, after a trial judge's injunction in August 2010 sought to bar funding for the research.

The Paragon Report provides investors with an excellent first step in their due diligence by providing daily trading ideas, and consolidating the public information available on them. For more investment research on the biotechnology industry register with us free at and get exclusive access to our numerous stock reports and industry newsletters.

In July, Advanced Cell Technology announced the dosing of the first patients in each of its two Phase ½ clinical trials for Stargardt's macular dystrophy and dry age-related macular degeneration using retinal pigment epithelial cells derived from human embryonic stem cells. ACT Chief Scientific Officer Dr. Robert Lanza explained that ACT scientists already tested the embryonic stem cells in animal models of the eye disease. He reports that visually impaired rats have experienced 100 percent improvement in visual performance over untreated animals.

Geron Corporation is developing cell therapy products from differentiated human embryonic stem cells for multiple indications, including central nervous system (CNS) disorders, heart failure, diabetes and osteoarthritis, and has initiated a Phase 1 clinical trial in spinal cord injury.

The Paragon Report has not been compensated by any of the above-mentioned publicly traded companies. Paragon Report is compensated by other third party organizations for advertising services. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at